FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2506835442> ?p ?o ?g. }

• W2506835442 abstract "Introduction: About 32% of men with high-risk prostate cancer have comorbidities, conditions that may be under-represented in randomized clinical trials (RCTs). Because men enrolled on RCTs are often excluded if they have multiple comorbidities, these patients may be at higher risk for serious toxicities from cancer therapies that the results of RCTs may not reflect. This study was undertaken to test the hypothesis that 90-day mortality rates in men undergoing treatment with abiraterone (a novel agent for treating castration-resistant prostate cancer) in the community settings is higher than that observed in the pivotal trial. Methods: SEER-Medicare linked data with Medicare Drug Event File during the period 2006-2012 were used to identify patients who filled prescriptions for abiraterone during the study period and these patients were followed through 12/31/2013 for overall mortality. Ninety-day mortality after abiraterone initiation among patients with Charlson score 0 was compared to that in the pivotal abiraterone trial published in the New England Journal of Medicine 2011. Results: We identified 1,106 patients who took abiraterone during the study period. Among them, 484 (43.8%) were age 75 or older at the time of abiraterone initiation and 61 (5.5%) had comorbidity score 2 or higher. Hospitalization rates among those who had abiraterone were 0.09 per person month during the 6-month window before the initiation of abiraterone and 0.12 per person month within 3 months of drug initiation. The top five diagnoses for hospital admission after drug initiation were general symptoms (ICD-9 780), malignant neoplasm of prostate (ICD-9 185), respiratory abnormality (ICD-9 786), care involving rehabilitation (ICD-9 V57), and urinary tract infection (ICD-9 599). The 90-day all-cause mortality after drug initiation was 14.5% (95% 12.4% - 16.5%) in the entire study cohort, 13.0% (95% CI 10.4% - 15.7%) among those under age 75 and 16.3% (13.0% - 19.6%) among those 75 or older. The 90-day mortality was 15.5% (95% CI 12.2% - 18.8%), 12.8% (95% CI 6.2% - 19.3%), and 18.0% (95% CI 8.3% - 27.8%) among patients with comorbidity score 0, 1, and 2+ respectively. The 90-day mortality among patients with comorbidity 0 in the community settings is substantially higher than those found in the pivotal trial abiraterone arm (risk ratio 2.03; 95% CI 1.48 - 2.78) and control arm (risk ratio 1.43; 1.01 - 2.03). Conclusion: This first US national study shows that 90-day mortality after abiraterone among relatively healthy patients in the community settings is twice that observed in the pivotal trial abiraterone arm. Further studies are needed to improve selection of eligible patients and post-treatment monitoring. Citation Format: Grace L. Lu-Yao, Dirk F. Moore, Yong Lin, Timothy R. Rebbeck, Kitaw Demissie, David Rotter, Kimberly A. McGuigan, Anthony V. D’Amico. Short-term outcomes of abiraterone in community settings. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4305." @default.
• W2506835442 created "2016-08-23" @default.
• W2506835442 creator A5005424988 @default.
• W2506835442 creator A5009692912 @default.
• W2506835442 creator A5026667667 @default.
• W2506835442 creator A5046995239 @default.
• W2506835442 creator A5068005365 @default.
• W2506835442 creator A5069712789 @default.
• W2506835442 creator A5074868327 @default.
• W2506835442 creator A5090119133 @default.
• W2506835442 date "2016-07-15" @default.
• W2506835442 modified "2023-10-16" @default.
• W2506835442 title "Abstract 4305: Short-term outcomes of abiraterone in community settings" @default.
• W2506835442 doi "https://doi.org/10.1158/1538-7445.am2016-4305" @default.
• W2506835442 hasPublicationYear "2016" @default.
• W2506835442 type Work @default.
• W2506835442 sameAs 2506835442 @default.
• W2506835442 citedByCount "0" @default.
• W2506835442 crossrefType "proceedings-article" @default.
• W2506835442 hasAuthorship W2506835442A5005424988 @default.
• W2506835442 hasAuthorship W2506835442A5009692912 @default.
• W2506835442 hasAuthorship W2506835442A5026667667 @default.
• W2506835442 hasAuthorship W2506835442A5046995239 @default.
• W2506835442 hasAuthorship W2506835442A5068005365 @default.
• W2506835442 hasAuthorship W2506835442A5069712789 @default.
• W2506835442 hasAuthorship W2506835442A5074868327 @default.
• W2506835442 hasAuthorship W2506835442A5090119133 @default.
• W2506835442 hasConcept C121608353 @default.
• W2506835442 hasConcept C126322002 @default.
• W2506835442 hasConcept C143998085 @default.
• W2506835442 hasConcept C168563851 @default.
• W2506835442 hasConcept C2426938 @default.
• W2506835442 hasConcept C2775832370 @default.
• W2506835442 hasConcept C2776421732 @default.
• W2506835442 hasConcept C2777899217 @default.
• W2506835442 hasConcept C2779159551 @default.
• W2506835442 hasConcept C2780192828 @default.
• W2506835442 hasConcept C535046627 @default.
• W2506835442 hasConcept C61367390 @default.
• W2506835442 hasConcept C71924100 @default.
• W2506835442 hasConcept C98274493 @default.
• W2506835442 hasConceptScore W2506835442C121608353 @default.
• W2506835442 hasConceptScore W2506835442C126322002 @default.
• W2506835442 hasConceptScore W2506835442C143998085 @default.
• W2506835442 hasConceptScore W2506835442C168563851 @default.
• W2506835442 hasConceptScore W2506835442C2426938 @default.
• W2506835442 hasConceptScore W2506835442C2775832370 @default.
• W2506835442 hasConceptScore W2506835442C2776421732 @default.
• W2506835442 hasConceptScore W2506835442C2777899217 @default.
• W2506835442 hasConceptScore W2506835442C2779159551 @default.
• W2506835442 hasConceptScore W2506835442C2780192828 @default.
• W2506835442 hasConceptScore W2506835442C535046627 @default.
• W2506835442 hasConceptScore W2506835442C61367390 @default.
• W2506835442 hasConceptScore W2506835442C71924100 @default.
• W2506835442 hasConceptScore W2506835442C98274493 @default.
• W2506835442 hasLocation W25068354421 @default.
• W2506835442 hasOpenAccess W2506835442 @default.
• W2506835442 hasPrimaryLocation W25068354421 @default.
• W2506835442 hasRelatedWork W1557743911 @default.
• W2506835442 hasRelatedWork W1965486934 @default.
• W2506835442 hasRelatedWork W1971372294 @default.
• W2506835442 hasRelatedWork W2058586633 @default.
• W2506835442 hasRelatedWork W2077932195 @default.
• W2506835442 hasRelatedWork W2106058419 @default.
• W2506835442 hasRelatedWork W2154889318 @default.
• W2506835442 hasRelatedWork W2419163947 @default.
• W2506835442 hasRelatedWork W2570738213 @default.
• W2506835442 hasRelatedWork W2754589635 @default.
• W2506835442 hasRelatedWork W2955496831 @default.
• W2506835442 hasRelatedWork W2969992503 @default.
• W2506835442 hasRelatedWork W3092451531 @default.
• W2506835442 hasRelatedWork W3096529196 @default.
• W2506835442 hasRelatedWork W3107667404 @default.
• W2506835442 hasRelatedWork W3108142551 @default.
• W2506835442 hasRelatedWork W3110976525 @default.
• W2506835442 hasRelatedWork W3194095064 @default.
• W2506835442 hasRelatedWork W3212544729 @default.
• W2506835442 hasRelatedWork W2566831015 @default.
• W2506835442 isParatext "false" @default.
• W2506835442 isRetracted "false" @default.
• W2506835442 magId "2506835442" @default.
• W2506835442 workType "article" @default.